JP2021513507A - 心臓血管系への影響を低減した避妊薬組成物 - Google Patents

心臓血管系への影響を低減した避妊薬組成物 Download PDF

Info

Publication number
JP2021513507A
JP2021513507A JP2020538823A JP2020538823A JP2021513507A JP 2021513507 A JP2021513507 A JP 2021513507A JP 2020538823 A JP2020538823 A JP 2020538823A JP 2020538823 A JP2020538823 A JP 2020538823A JP 2021513507 A JP2021513507 A JP 2021513507A
Authority
JP
Japan
Prior art keywords
risk
estetrol
use according
component
preferably less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020538823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513507A5 (https=
JPWO2019154899A5 (https=
Inventor
モード ジョス，
モード ジョス，
グルヴァディ ロージン，
グルヴァディ ロージン，
Original Assignee
エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ
エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ, エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ filed Critical エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ
Publication of JP2021513507A publication Critical patent/JP2021513507A/ja
Publication of JP2021513507A5 publication Critical patent/JP2021513507A5/ja
Publication of JPWO2019154899A5 publication Critical patent/JPWO2019154899A5/ja
Priority to JP2023168039A priority Critical patent/JP7651645B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2020538823A 2018-02-07 2019-02-07 心臓血管系への影響を低減した避妊薬組成物 Pending JP2021513507A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023168039A JP7651645B2 (ja) 2018-02-07 2023-09-28 心臓血管系への影響を低減した避妊薬組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18155571.5 2018-02-07
EP18155571 2018-02-07
EP18160586.6 2018-03-07
EP18160586 2018-03-07
PCT/EP2019/052980 WO2019154899A1 (en) 2018-02-07 2019-02-07 Contraceptive composition with reduced cardiovascular effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023168039A Division JP7651645B2 (ja) 2018-02-07 2023-09-28 心臓血管系への影響を低減した避妊薬組成物

Publications (3)

Publication Number Publication Date
JP2021513507A true JP2021513507A (ja) 2021-05-27
JP2021513507A5 JP2021513507A5 (https=) 2022-02-15
JPWO2019154899A5 JPWO2019154899A5 (https=) 2022-02-15

Family

ID=65278388

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020538823A Pending JP2021513507A (ja) 2018-02-07 2019-02-07 心臓血管系への影響を低減した避妊薬組成物
JP2023168039A Active JP7651645B2 (ja) 2018-02-07 2023-09-28 心臓血管系への影響を低減した避妊薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023168039A Active JP7651645B2 (ja) 2018-02-07 2023-09-28 心臓血管系への影響を低減した避妊薬組成物

Country Status (20)

Country Link
EP (2) EP4140489A1 (https=)
JP (2) JP2021513507A (https=)
KR (1) KR102717921B1 (https=)
CN (2) CN111683664A (https=)
AU (1) AU2019219070B2 (https=)
CA (2) CA3178181A1 (https=)
CL (1) CL2020002017A1 (https=)
EC (1) ECSP20054822A (https=)
GE (2) GEAP202215414A (https=)
IL (1) IL276584B2 (https=)
JO (1) JOP20200169A1 (https=)
MA (1) MA51733A (https=)
NZ (1) NZ766027A (https=)
PH (1) PH12020500601A1 (https=)
PY (1) PY1908892A (https=)
SG (1) SG11202007163WA (https=)
TW (1) TWI845496B (https=)
UA (1) UA126746C2 (https=)
UY (1) UY38075A (https=)
WO (1) WO2019154899A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077454A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
MD3310333T2 (ro) 2015-06-18 2020-06-30 Estetra Sprl Unitate de dozare orodispersabilă care conține un component estetrol
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
DK3781171T3 (da) 2018-04-19 2022-05-02 Estetra Srl Sammensætninger og deres anvendelser til lindring af menopause-associerede symptomer
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) * 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022248733A1 (en) 2021-05-28 2022-12-01 Neuralis Sa Use of estetrol in treatment of respiratory infection diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527413A (ja) * 2009-05-22 2012-11-08 バイエル ファーマ アクチエンゲゼルシャフト 少なくとも一つのエストロゲン、及び／又は少なくとも一つゲスターゲン、及び少なくとも一つのプロバイオティック細菌株を含む、経口投与医薬
JP2016540021A (ja) * 2013-12-12 2016-12-22 ドネスタ バイオサイエンス ビー．ブイ．Ｄｏｎｅｓｔａ Ｂｉｏｓｃｉｅｎｃｅ Ｂ．Ｖ． エステトロール成分を含有する口腔内崩壊固体単位剤形

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
EP1390042B1 (en) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
CA3178291A1 (en) * 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
KR102780201B1 (ko) 2016-10-28 2025-03-12 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527413A (ja) * 2009-05-22 2012-11-08 バイエル ファーマ アクチエンゲゼルシャフト 少なくとも一つのエストロゲン、及び／又は少なくとも一つゲスターゲン、及び少なくとも一つのプロバイオティック細菌株を含む、経口投与医薬
JP2016540021A (ja) * 2013-12-12 2016-12-22 ドネスタ バイオサイエンス ビー．ブイ．Ｄｏｎｅｓｔａ Ｂｉｏｓｃｉｅｎｃｅ Ｂ．Ｖ． エステトロール成分を含有する口腔内崩壊固体単位剤形

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CONTRACEPTION, vol. 95, JPN6022050198, 2017, pages 140 - 147, ISSN: 0005086888 *
EMBO MOLECULAR MEDICINE, vol. 6, no. 10, JPN6022050201, 2014, pages 1328 - 1346, ISSN: 0004932009 *
THE EUROPEAN JOURNAL OF CONTRACEPTION & REPRODUCTIVE HEALTH CARE, vol. 22, no. 4, JPN6022050200, 2017, pages 260 - 267, ISSN: 0005086889 *

Also Published As

Publication number Publication date
EP3749327A1 (en) 2020-12-16
EP4140489A1 (en) 2023-03-01
CN115429806A (zh) 2022-12-06
JP7651645B2 (ja) 2025-03-26
AU2019219070B2 (en) 2024-12-19
CN111683664A (zh) 2020-09-18
CA3178181A1 (en) 2019-08-15
CL2020002017A1 (es) 2020-12-04
WO2019154899A1 (en) 2019-08-15
IL276584B1 (en) 2024-06-01
KR102717921B1 (ko) 2024-10-16
TWI845496B (zh) 2024-06-21
UY38075A (es) 2019-10-01
ECSP20054822A (es) 2020-12-31
AU2019219070A1 (en) 2020-09-24
TW202011967A (zh) 2020-04-01
CA3089804A1 (en) 2019-08-15
PY1908892A (es) 2019-10-15
SG11202007163WA (en) 2020-08-28
GEAP202215414A (en) 2022-04-25
PH12020500601A1 (en) 2021-05-17
MA51733A (fr) 2020-12-16
JP2024009834A (ja) 2024-01-23
KR20200118464A (ko) 2020-10-15
IL276584B2 (en) 2024-10-01
UA126746C2 (uk) 2023-01-18
NZ766027A (en) 2026-03-27
GEP20227407B (en) 2022-08-25
IL276584A (en) 2020-09-30
JOP20200169A1 (ar) 2020-07-07

Similar Documents

Publication Publication Date Title
JP7651645B2 (ja) 心臓血管系への影響を低減した避妊薬組成物
JP6557298B2 (ja) 副作用（ｖｔｅリスク、頭痛）を軽減し、月経困難症および月経痛の症状を軽減する方法
US20200046729A1 (en) Methods using combined oral contraceptive compositions with reduced cardiovascular effects
Klipping et al. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism
KR102780201B1 (ko) 월경통 및 생리통의 관리방법
Boldo et al. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies
Keam et al. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive
EP1494678A1 (en) Method of hormonal therapy
EP1558265A1 (en) Cardiovascular protection using anti-aldosteronic progestins
Burkman Lipid metabolism effects with desogestrel-containing oral contraceptives
US7786101B2 (en) Cardiovascular protection using anti-aldosteronic progestins
US20250360147A1 (en) Methods using combined oral contraceptive compositions with reduced cardiovascular effects
HK40081220A (en) Contraceptive composition with reduced cardiovascular effects
EA048537B1 (ru) Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы
EA048171B1 (ru) Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы
Curran et al. Estradiol and norgestimate: A review of their combined use as hormone replacement therapy in postmenopausal women
Aldrighi et al. Lipid profile in women over 35 years old using triphasic combined oral contraceptives
Antoniou-Tsigkos et al. Combined oral contraceptives: Why, when, where?
Gaspard et al. ORIGINAL STUDY
Palshetkar et al. Tackling PCOS with Hormonal Contraceptives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200915

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230620